China Resources Pharma reiterates positive growth and margin expansion for 2026, but policy and collection pressures remain to be monitored

Overview

This report summarizes Goldman Sachs' discussions with China Resources Pharmaceuticals at China Healthcare Corporate Day 2026. Management reiterated its guidance for positive revenue growth and margin expansion in 2026 and believes profit growth could outpace revenue growth. At the same time, it acknowledged that recent pharmaceutical anti-corruption policies, centralized procurement price cuts, and extended collection cycles are creating short-term operating pressure. The report also reviews the operating performance of major manufacturing subsidiaries, the expansion of the CSO and medical device businesses, and a more disciplined M&A direction.

Core views

The core view is that China Resources Pharmaceuticals' core businesses still have positive growth prospects, while group margins could benefit from reduced impairment and financing cost savings. However, policy disruptions and a weak industry recovery limit near-term upside. Manufacturing subsidiaries are showing divergent performance: Sanjiu remains relatively stable, Tasly's core products are trending well, Boya is affected by VBP price cuts for blood products, and Double Crane's injectable prices and demand are stable while it advances its synthetic biology business. The company is positioning CSO and medical devices as new growth drivers, but their current revenue contribution remains small, making execution pace and profitability validation critical.

Analysis framework

Goldman Sachs applies a sum-of-the-parts valuation to assess the company's value: the manufacturing business is valued at RMB34.8bn based on a five-year exit P/E of 9x and a five-year EPS CAGR of 9%; the distribution business is valued at RMB10.7bn based on a five-year exit P/E of 5x and a five-year EPS CAGR of 5%; and group-level expenses are valued at negative RMB10.7bn based on a five-year exit P/E of 6x and a five-year CAGR of 6%. The report also combines management commentary from the conference with qualitative assessments of policy impacts, subsidiary operations, cash collection, CSO, medical devices, and M&A direction.

Methodology notes

• Valuation methodsSum-of-the-parts valuation

  Value the manufacturing, distribution, and group expense segments separately and combine them to derive the target price

  The report separately values the manufacturing business, distribution business, and group-level expenses using different exit P/E multiples and growth assumptions, ultimately deriving a 12-month target price of HK$6.03.

• Factor profileGS Factor Profile

  Compare stock characteristics across growth, financial returns, valuation multiples, and composite metrics

  Goldman Sachs' factor profile compares the company's standardized rankings in growth, financial returns, valuation multiples, and overall performance relative to the broader market and industry peers.

• M&A assessmentM&A Rank

  Assess the potential probability of a company becoming an M&A target

  Goldman Sachs' M&A framework uses a rating from 1 to 3 to measure the potential probability of acquisition. This report primarily discusses China Resources Pharmaceuticals' own M&A strategy, emphasizing management's more disciplined focus on core healthcare areas.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• 03320.HK

  Covered company and Hong Kong-listed company

  Strengths

  Guidance for positive revenue growth in 2026, faster profit growth than revenue, financing cost savings, year-on-year decline in impairment pressure, and expansion of the CSO and medical device businesses.

  Weaknesses

  Hospital channels are significantly affected by anti-corruption policies, non-VBP drug collection cycles are lengthening, and certain manufacturing subsidiaries show divergent performance.

  Comparison

  The report places the company within the China healthcare coverage universe and maintains a Neutral rating relative to peers.

  Risks

  Manufacturing subsidiary growth below expectations, broader VBP impacts, and distribution growth below expectations due to a weak industry recovery.

Key data

• RatingNeutralGoldman Sachs maintains its Neutral rating on China Resources Pharmaceuticals.
• 12-month target priceHK$6.03The target price is derived from the sum-of-the-parts valuation.
• Disclosed priceHK$4.31The China Resources Pharmaceuticals price listed in the company-specific disclosure.
• Manufacturing business valuationRMB34.8bnBased on a five-year exit P/E of 9x and a five-year EPS CAGR of 9%.
• Distribution business valuationRMB10.7bnBased on a five-year exit P/E of 5x and a five-year EPS CAGR of 5%.
• Group-level expense valuationNegative RMB10.7bnBased on a five-year exit P/E of 6x and a five-year CAGR of 6%.
• CSO business targetAchieve profitability in 2026The company has secured initial contracts from multinational pharmaceutical companies, including Pfizer, but revenue contribution remains small.

Impact & implications

The investment implication is that China Resources Pharmaceuticals faces short-term pressure from anti-corruption measures, centralized procurement, and a weak industry recovery. However, increased CSO platform scale, progress in medical devices, and realized M&A synergies could still create new growth pillars. The Neutral rating reflects Goldman Sachs' recognition of positive growth and margin improvement, as well as its caution regarding policy pressure, divergent manufacturing subsidiary performance, and the pace of distribution recovery.

Risks

• Manufacturing subsidiary growth is slower than expected.
• The scope of VBP impacts expands or pricing pressure deepens.
• Distribution growth falls below expectations due to a weak industry recovery.
• The short-term drag of anti-corruption policies on hospital channels and manufacturing profitability persists.
• Cash collection cycles for non-VBP drugs lengthen further.
• M&A synergies or profitability of new businesses are realized more slowly than expected.

What to watch

• Execution of positive revenue growth in 2026 and profit growth outpacing revenue growth.
• The subsequent impact of anti-corruption policies on hospital channels, CR Double Crane, and manufacturing business margins.
• Changes in cash collection cycles for non-VBP and VBP drugs.
• CSO platform contract conversion, scaling progress, and the 2026 profitability target.
• Post-M&A integration and growth in medical devices, especially orthopedics and IVD.
• M&A pace and valuation discipline in core healthcare areas including blood products, vaccines, medical devices, and traditional Chinese medicine.